Immunome Q3 net loss $57.5M; cash $272.6M; varegacestat data due by year-end

Immunome Inc.

2025-Q3 EPS reported -$1.68 vs consensus -$0.59 ▼ miss (-186.8%)

Net loss of $57.5M for Q3 2025; cash and equivalents $272.6M.
Expects topline data from Phase 3 RINGSIDE (varegacestat) before end of 2025.
IM-1021 shows objective responses in B-cell lymphoma; initial data in 2026.
HC74 payload overcomes multi-drug resistance in preclinical models.
Cash runway into 2027; three preclinical ADCs targeting 2026 IND submissions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.